# Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

> **NCT00366548** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 500 (actual)

## Conditions studied

- Vaccines, Pneumococcal

## Interventions

- **BIOLOGICAL:** 13 valent pneumococcal conjugate vaccine with Polysorbate 80
- **BIOLOGICAL:** 13 valent pneumococcal conjugate vaccine without Polysorbate 80

## Key facts

- **NCT ID:** NCT00366548
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2012-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00366548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00366548, "Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00366548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*